Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-14

Clinical Trial Update: Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update comparing Nova22007 to vehicle in vernal keratoconjunctivitis (phase 2/3) with completed status and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NOVA22007 (cyclosporin)

Snippet

Sponsor: Santen SAS | Conditions: Conjunctivitis, Vernal | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-12-14